News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
222,896 Results
Type
Article (9330)
Company Profile (20)
Press Release (213546)
Section
Business (68255)
Career Advice (132)
Deals (11898)
Drug Delivery (13)
Drug Development (31779)
Employer Resources (20)
FDA (5232)
Job Trends (4844)
News (115068)
Policy (7836)
Tag
Academia (729)
Alliances (11699)
Alzheimer's disease (564)
Approvals (5229)
Artificial intelligence (57)
Bankruptcy (96)
Best Places to Work (4475)
Breast cancer (66)
Cancer (607)
Cardiovascular disease (53)
Career advice (114)
Cell therapy (106)
Clinical research (26377)
Collaboration (165)
Compensation (61)
COVID-19 (567)
C-suite (38)
Cystic fibrosis (45)
Data (677)
Diabetes (45)
Diagnostics (1998)
Earnings (35793)
Events (47992)
Executive appointments (125)
FDA (5467)
Funding (217)
Gene therapy (62)
GLP-1 (177)
Government (1003)
Healthcare (5968)
Infectious disease (592)
Inflammatory bowel disease (51)
IPO (6706)
Job creations (628)
Job search strategy (104)
Layoffs (69)
Legal (1377)
Lung cancer (119)
Manufacturing (57)
Medical device (4349)
Medtech (4351)
Mergers & acquisitions (5258)
Metabolic disorders (122)
Neuroscience (696)
NextGen Class of 2024 (2118)
Non-profit (1136)
Northern California (740)
Obesity (65)
Opinion (57)
Parkinson's disease (46)
People (16299)
Phase I (6609)
Phase II (11199)
Phase III (10320)
Pipeline (245)
Postmarket research (1188)
Preclinical (2945)
Radiopharmaceuticals (83)
Rare diseases (95)
Real estate (1217)
Regulatory (5882)
Research institute (656)
Series A (44)
Series B (35)
Southern California (629)
Startups (2379)
United States (5827)
Vaccines (118)
Weight loss (36)
Date
Today (74)
Last 7 days (501)
Last 30 days (2122)
Last 365 days (14964)
2024 (13745)
2023 (15538)
2022 (19865)
2021 (19920)
2020 (18886)
2019 (15720)
2018 (11951)
2017 (10962)
2016 (10125)
2015 (12449)
2014 (9166)
2013 (6850)
2012 (7504)
2011 (8151)
2010 (7513)
Location
Africa (135)
Arizona (46)
Asia (11934)
Australia (1741)
California (1581)
Canada (635)
China (119)
Colorado (69)
Connecticut (86)
Delaware (45)
Europe (28661)
Florida (168)
Georgia (41)
Illinois (129)
Indiana (87)
Japan (44)
Maryland (212)
Massachusetts (1252)
Michigan (43)
Minnesota (93)
New Jersey (454)
New York (431)
North Carolina (253)
Northern California (740)
Ohio (58)
Pennsylvania (313)
South America (236)
Southern California (629)
Texas (197)
Utah (40)
Washington State (165)
222,896 Results for "warburg pincus ventures l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Advent International and Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business
Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, announced the completion of their previously announced acquisition of Baxter International Inc.’s BioPharma Solutions business.
October 2, 2023
·
4 min read
BioMidwest
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion
Baxter International Inc., a leading global medtech company, announced that it has signed a definitive agreement to divest its BioPharma Solutions business to Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor.
May 8, 2023
·
9 min read
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
Ono Pharmaceutical Co., Ltd. announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P., which was established as a corporate venture capital fund in CA, USA in May 2020.
December 1, 2023
·
1 min read
J.P. Morgan Raises Over $500M for First Biotech Venture Capital Fund
J.P. Morgan’s life sciences venture capital arm on Thursday announced it closed its first biotech fund, targeting companies in cardiometabolic disease, immunology, oncology and genetic medicine.
June 14, 2024
·
2 min read
·
Tyler Patchen
Biotech Bay
Bioluminescence Ventures Emerges from Stealth with $477M AUM
Bioluminescence Ventures today announced its emergence from stealth with $477M in assets under management across two funds: Bioluminescence Ventures Fund I, L.P., and Bioluminescence Ventures Fund II, L.P.
November 1, 2023
·
5 min read
Pharm Country
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.
March 27, 2024
·
7 min read
Business
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
Daxor Corporation today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer.
June 5, 2024
·
4 min read
Policy
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.
December 1, 2023
·
6 min read
Startups
BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture
With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.
August 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Nodenza Venture Partners invests in Trellis Bioscience
October 23, 2024
·
5 min read
1 of 22,290
Next